Global Medical Radiation Detection Market (2021 to 2030) – Growing Use of Nuclear Medicine and Radiation Therapy for Diagnosis and Treatment –

DUBLIN–(BUSINESS WIRE)–The “Medical Radiation Detection Market by Detection Type, Product, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to’s offering. The global medical radiation detection market was valued at $1,173.0 million in 2020 and is projected to reach $2,558.1 million by 2030, registering a CAGR of 8.4% from … [Read more…]

Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19

PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is authorized by the U.S. FDA for emergency use in both high-risk adults and high-risk pediatric patients 12 years of age and older weighing at least 40 kg A total of 20 million treatment courses will be delivered to the U.S. government in 2022, with approximately 10 million … [Read more…]

Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

CT-P63 demonstrated a well- established safety profile in the global Phase I trial CT-P63 maintained strong neutralising ability against the Omicron variant (B.1.1.529) based on structural analysis by X-ray crystallography and neutralisation data from pseudo- virus testing Celltrion plans to provide dual treatment options for COVID-19; Regkirona™ for hospitalised patients and a nebulised cocktail therapy … [Read more…]

Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19

PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) includes nirmatrelvir, a protease inhibitor that was specifically designed to combat SARS-CoV-2 A total of 2.75 million doses expected to be delivered to the UK through 2022, subject to regulatory approval or authorization Pfizer is seeking Conditional Marketing Authorization of PAXLOVID with the MHRA and is working to … [Read more…]

ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing

Year-End Review: SISONKE Universal Boost COVID T-Cell vaccine trial initiates Phase 3 enrollment in South Africa in previously vaccinated participants Increased GMP manufacturing capacity for RNA, DNA, Subunit Proteins, and Adjuvants vaccine platforms in U.S., South Africa, and Botswana Non-Muscle Invasive Bladder Cancer (NMIBC) planned data cutoff in January 2022 with median follow-up exceeding 24-months … [Read more…]

EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate

EMA’s CHMP advice states that PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) can be used for treatment of adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease This advice could support authorities of EU Member States regarding the supply and use of PAXLOVID prior … [Read more…]

EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study

Only antibody authorized in the US for pre-exposure prophylaxis of COVID-19 WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data. In this study, EVUSHELD’s Inhibitory Concentration 50 (IC50), a measure of neutralizing potency … [Read more…]

Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

– IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern – IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well as natural viral clearance mechanisms EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its … [Read more…]

$11+ Billion Respiratory Protection Equipment Markets – Global Forecasts from 2021 to 2026 –

DUBLIN–(BUSINESS WIRE)–The “Respiratory Protection Equipment Market – Forecasts from 2021 to 2026” report has been added to’s offering. The global respiratory protection equipment market is evaluated at US$ 6.879 billion for the year 2019 growing at a CAGR of 7.04% reaching the market size of US$ 11.076 billion by the year 2026. Regulations by … [Read more…]

Celltrion’s Monoclonal Antibody Treatment regdanvimab, Approved by the European Commission for the Treatment of COVID-19

The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week (11/11/2021) Celltrion continues to discuss supply agreements with regulatory agencies and contractors in more than 30 countries in Europe, Asia and LATAM to accelerate global access … [Read more…]